Tuberous sclerosis

From Libre Pathology
Revision as of 13:08, 14 October 2019 by Jensflorian (talk | contribs) (→‎Associations: Tubers moved into separate page)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Micrograph showing a renal angiomyolipoma, as may be seen in tuberous sclerosis. H&E stain. (WC/KGH)

Tuberous sclerosis, also tuberous sclerosis complex (abbreviated TSC), is an autosomal dominant syndrome associated with an increased risk of hamartomas and some risk increase for malignant tumours.

Historically described as:[1]

  1. Epilepsy.
  2. Mental retardation.
  3. Adenoma sebaceum (angiofibromas).

Diagnostic consensus criteria published (2012, OpenAcess).

Also called Bourneville-Pringle disease.

General

  • Autosomal dominant with variable penetrance.[2]
  • Majority (60-70%) are de novo mutations.[2]
  • May be treated with a mTOR inhibitor, e.g. everolimus.[3]

Associations

Pathologic:


Note:

  • The same genes (TSC1, TSC2) are implicated in PEComas.
  • Renal lesions are seen in ~60% of patients.[4]


thumb300px

  • Scheme illustrates types of neuropathologic changes in tuberous sclerosis complex. 1- isolated balloon cells in white matter, TSC-/-; 2- heterotopic cluster with dysplastic neurons TSC-/+; 3- subependymal nodules and 4- subependymal giant cell astrocytoma in ependyma of third ventricle (note that this is not usual localisation for both lesions, which is rather ependyma of lateral ventricles) 5- cortical tuber; 6 - linear migration streak. This scheme is based on DiMario, F Brain abnormalities in Tuberous Sclerosis Complex J Child Neurol, 9, 650-657. 2004.[9]


Mnemonic SALSA HEART:[10]

Genes

  • TSC1.[13]
  • TSC2.[14]
    • Some evidence to suggest it is more often implicated in malignant tumours (than TSC1).[15]
    • TSC2 mutations have a higher prevalence (than TSC1 mutations) and are considered more aggressive.[4]

Notes:

  • The proteins (hamartin and tuberin) are expressed in a wide variety of tissues.[16]

Incidence

~1 in 10,000 population.[1][15]

See also

References

  1. 1.0 1.1 URL: http://emedicine.medscape.com/article/1177711-overview. Accessed on: 13 February 2011.
  2. 2.0 2.1 2.2 2.3 2.4 Guo, J.; Tretiakova, MS.; Troxell, ML.; Osunkoya, AO.; Fadare, O.; Sangoi, AR.; Shen, SS.; Lopez-Beltran, A. et al. (Nov 2014). "Tuberous Sclerosis-associated Renal Cell Carcinoma: A Clinicopathologic Study of 57 Separate Carcinomas in 18 Patients.". Am J Surg Pathol 38 (11): 1457-67. doi:10.1097/PAS.0000000000000248. PMID 25093518.
  3. Pirson, Y. (Jul 2013). "Tuberous sclerosis complex-associated kidney angiomyolipoma: from contemplation to action.". Nephrol Dial Transplant 28 (7): 1680-5. doi:10.1093/ndt/gft009. PMID 23413089.
  4. 4.0 4.1 4.2 4.3 4.4 Rakowski SK, Winterkorn EB, Paul E, Steele DJ, Halpern EF, Thiele EA (November 2006). "Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors". Kidney Int. 70 (10): 1777–82. doi:10.1038/sj.ki.5001853. PMID 17003820.
  5. Grajkowska, W.; Kotulska, K.; Jurkiewicz, E.; Roszkowski, M.; Daszkiewicz, P.; Jóźwiak, S.; Matyja, E. (2011). "Subependymal giant cell astrocytomas with atypical histological features mimicking malignant gliomas.". Folia Neuropathol 49 (1): 39-46. PMID 21455842.
  6. Kobayashi, T.; Satoh, K.; Ohkawa, M. (Feb 2005). "Multifocal micronodular pneumocyte hyperplasia associated with tuberous sclerosis.". Acta Radiol 46 (1): 37-40. PMID 15841738.
  7. Kobashi, Y.; Sugiu, T.; Mouri, K.; Irei, T.; Nakata, M.; Oka, M. (Jun 2008). "Multifocal micronodular pneumocyte hyperplasia associated with tuberous sclerosis: differentiation from multiple atypical adenomatous hyperplasia.". Jpn J Clin Oncol 38 (6): 451-4. doi:10.1093/jjco/hyn042. PMID 18535095.
  8. Cotter, JA. (Apr 2019). "An update on the central nervous system manifestations of tuberous sclerosis complex.". Acta Neuropathol. doi:10.1007/s00401-019-02003-1. PMID 30976976.
  9. DiMario, FJ. (Sep 2004). "Brain abnormalities in tuberous sclerosis complex.". J Child Neurol 19 (9): 650-7. doi:10.1177/08830738040190090401. PMID 15563010.
  10. URL: http://www.usmle-forums.com/usmle-step-1-mnemonics/303-tuberous-sclerosis.html. Accessed on: 20 October 2011.
  11. URL: http://dermatology-s10.cdlib.org/1611/articles/3_2009-11-17/batra.html. Accessed on: 18 February 2012.
  12. Jindal, R.; Jain, A.; Gupta, A.; Shirazi, N. (Jun 2013). "Ash-leaf spots or naevus depigmentosus: a diagnostic challenge.". BMJ Case Rep 2013. doi:10.1136/bcr-2012-007008. PMID 23761491.
  13. Online 'Mendelian Inheritance in Man' (OMIM) 605284
  14. Online 'Mendelian Inheritance in Man' (OMIM) 191092
  15. 15.0 15.1 Al-Saleem T, Wessner LL, Scheithauer BW, et al. (November 1998). "Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex". Cancer 83 (10): 2208–16. PMID 9827727.
  16. Johnson, MW.; Kerfoot, C.; Bushnell, T.; Li, M.; Vinters, HV. (Mar 2001). "Hamartin and tuberin expression in human tissues.". Mod Pathol 14 (3): 202-10. doi:10.1038/modpathol.3880286. PMID 11266527.